



**Division of Medical Services  
Pharmacy Program**

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437  
Phone: 501-683-4120 · Fax: 1-800-424-5851



**MEMORANDUM**

TO: Arkansas Medicaid Enrolled Prescribing Providers and Pharmacy Providers

FROM: Cynthia Neuhofer, Pharm.D. Division of Medical Services Pharmacy Program

A handwritten signature in black ink that reads "Cynthia Neuhofer".

DATE: February 8, 2021

SUBJ: New ADHD edits beginning February 10, 2021

Notification of the upcoming ADHD changes was made available in the provider memo posted on the Medicaid website in November 2020.

[https://arkansas.magellanrx.com/client/docs/provider\\_memos/ProvMem-20180131.pdf](https://arkansas.magellanrx.com/client/docs/provider_memos/ProvMem-20180131.pdf)

You should have received an email notifying you that the newest provider memo had been posted.

Below is a summary of the upcoming ADHD changes **effective February 10, 2021**.

- a. For children--increase minimum age and expand maximum age
  - The minimum age for all CII stimulants and atomoxetine has been changed from  $\geq 5$  years to  $\geq 6$  years of age to better correlate with the manufacturer's package insert.
    - **Recipients  $\leq 5$  years of age require a PA.**
  - The maximum age to be considered a "child" when prescribed a CII stimulant has changed. Currently, recipients  $\geq 18$  years of age require a PA for every request.
    - Recipients  $\geq 19$  years of age are **now** considered an adult in the treatment of ADHD. The change will allow **recipients 6-18 years** of age to receive a **preferred** medication without a PA if they meet current therapeutic duplication, quantity requirements, and swallow criteria.
  - These changes would apply to preferred and nonpreferred medications.
- b. Require a billed diagnosis of ADHD
  - A billed diagnosis of ADHD is required in the last 2 years to allow POS claims to process for children 6-18 years of age.
  - If the ADHD diagnosis is not billed, a PA will be required.
    - Prescriber would need to submit documentation of an ADHD diagnosis with current chart notes.
    - If recipient does not have ADHD, a letter of medical necessity would need to be provided
  - The goal is to prevent off-label use of CII stimulants in children.
  - Atomoxetine (Strattera®) will also require a billed diagnosis of ADHD for children **AND** adults. If the recipient does not have a billed diagnosis of ADHD in the last 2 years, atomoxetine will require a prior authorization.
- c. For adults—recipients  $\geq 19$  years of age

- Prior authorization will continue to be required. Prescriber must submit the following with each request:
  - Current chart notes
  - Completed adult CII stimulant form with each request, and the form can be found online
  - The form has been updated



ARRx\_SMN\_Adult\_C  
-II\_Stimulant2.pdf

- For diagnosis other than ADHD, provide documentation of the medical necessity.
- d.** For those recipients who do not have a billed diagnosis of ADHD in their medical history, yet have been compliant on their ADHD treatment, please call the Magellan Help Desk at 1-800-424-7895 for assistance. This is to allow the child to continue to receive his/her medication without a delay in treatment. We will accept requests for a PA from the prescriber's clinical representative or the pharmacist filling the prescription.